Dimension Therapeutics Company Profile (NASDAQ:DMTX)

About Dimension Therapeutics (NASDAQ:DMTX)

Dimension Therapeutics logoDimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DMTX
  • CUSIP: N/A
  • Web: www.dimensiontx.com
Capitalization:
  • Market Cap: $26.3 million
  • Outstanding Shares: 25,043,000
Average Prices:
  • 50 Day Moving Avg: $1.37
  • 200 Day Moving Avg: $2.82
  • 52 Week Range: $1.05 - $10.47
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.58
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $12.88 million
  • Price / Sales: 2.04
  • Book Value: $1.90 per share
  • Price / Book: 0.55
Profitability:
  • EBIDTA: ($51,060,000.00)
  • Net Margins: -464.39%
  • Return on Equity: -50.07%
  • Return on Assets: -37.10%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 5.43%
  • Quick Ratio: 5.43%
Misc:
  • Average Volume: 109,469 shs.
  • Beta: 3.97
  • Short Ratio: 1.89
 

Frequently Asked Questions for Dimension Therapeutics (NASDAQ:DMTX)

What is Dimension Therapeutics' stock symbol?

Dimension Therapeutics trades on the NASDAQ under the ticker symbol "DMTX."

How were Dimension Therapeutics' earnings last quarter?

Dimension Therapeutics Inc (NASDAQ:DMTX) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.03. The firm had revenue of $3.62 million for the quarter. Dimension Therapeutics had a negative net margin of 464.39% and a negative return on equity of 50.07%. View Dimension Therapeutics' Earnings History.

Where is Dimension Therapeutics' stock going? Where will Dimension Therapeutics' stock price be in 2017?

5 analysts have issued 12-month target prices for Dimension Therapeutics' shares. Their forecasts range from $1.50 to $20.00. On average, they expect Dimension Therapeutics' share price to reach $8.30 in the next year. View Analyst Ratings for Dimension Therapeutics.

What are analysts saying about Dimension Therapeutics stock?

Here are some recent quotes from research analysts about Dimension Therapeutics stock:

  • 1. According to Zacks Investment Research, "Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. " (5/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are lowering our rating to Neutral from Overweight and price target to $3 from $32, following initial results from Dimension's Phase 1/2 Study with DTX101 in Hemophilia B. Results highlighted that DTX101 will require additional optimization to be competitive with currently ongoing Hemophilia B gene therapy programs. While DTX101 was able to achieve meaningful peak FIX levels, these levels declined significantly in all patients. In addition, five of six patients demonstrated elevated levels of ALTs, which could hinder the company's ability to dose higher. Seeing the need for additional optimization for the hemophilia B program, we are moving to the sidelines and adjusting our price target." (1/31/2017)

Are investors shorting Dimension Therapeutics?

Dimension Therapeutics saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 334,958 shares, a decline of 7.1% from the March 31st total of 360,394 shares. Based on an average trading volume of 116,341 shares, the days-to-cover ratio is presently 2.9 days.

Who are some of Dimension Therapeutics' key competitors?

Who are Dimension Therapeutics' key executives?

Dimension Therapeutics' management team includes the folowing people:

  • Georges Gemayel Ph.D., Chairman of the Board
  • Annalisa Jenkins, President, Chief Executive Officer, Director
  • Jean M. Franchi CPA, Chief Financial Officer
  • Mary T. Thistle, Chief Operating Officer
  • Samuel C. Wadsworth Ph.D., Chief Scientific Officer
  • Eric Crombez M.D., Chief Medical Officer
  • John Hohneker, Director
  • Alan B. Colowick M.D., Independent Director
  • Michael Dybbs Ph.D., Independent Director
  • George V. Migausky, Independent Director

Who owns Dimension Therapeutics stock?

Dimension Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (19.54%), FIL Ltd (6.74%), Vanguard Group Inc. (2.68%), Weiss Multi Strategy Advisers LLC (1.56%), Geode Capital Management LLC (0.58%) and Two Sigma Securities LLC (0.25%). Company insiders that own Dimension Therapeutics stock include K Reed Clark and Rishi Gupta. View Institutional Ownership Trends for Dimension Therapeutics.

Who bought Dimension Therapeutics stock? Who is buying Dimension Therapeutics stock?

Dimension Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Securities LLC, Weiss Multi Strategy Advisers LLC, Vanguard Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Dimension Therapeutics.

How do I buy Dimension Therapeutics stock?

Shares of Dimension Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dimension Therapeutics' stock price today?

One share of Dimension Therapeutics stock can currently be purchased for approximately $1.05.


MarketBeat Community Rating for Dimension Therapeutics (NASDAQ DMTX)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Dimension Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dimension Therapeutics (NASDAQ:DMTX) (?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $8.30 (690.48% upside)

Analysts' Ratings History for Dimension Therapeutics (NASDAQ:DMTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017Citigroup IncDowngradeBuy -> Neutral$1.50HighView Rating Details
3/11/2017Canaccord GenuitySet Price TargetBuy$20.00HighView Rating Details
3/11/2017Cantor FitzgeraldSet Price TargetHold$3.00HighView Rating Details
2/2/2017Jefferies Group LLCReiterated RatingBuy$7.00N/AView Rating Details
8/21/2016Chardan CapitalSet Price TargetHold$10.00N/AView Rating Details
3/30/2016Goldman Sachs Group IncDowngradeBuy -> Neutral$10.00N/AView Rating Details
12/3/2015Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
11/6/2015Roth CapitalInitiated CoverageBuy$31.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Dimension Therapeutics (NASDAQ:DMTX)
Earnings by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Earnings History by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.52)($0.54)$3.62 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.56)($0.53)$3.04 million$4.10 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.56)($0.58)$2.37 million$2.76 millionViewN/AView Earnings Details
8/11/2016Q2 2016($0.43)($0.49)$2.21 million$2.37 millionViewN/AView Earnings Details
5/12/2016Q116($0.57)($0.38)$2.24 million$2.21 millionViewN/AView Earnings Details
3/24/2016Q4 2015($0.38)($0.45)$1.70 million$2.35 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dimension Therapeutics (NASDAQ:DMTX)
2017 EPS Consensus Estimate: ($2.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.53)($0.53)($0.53)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.55)($0.55)($0.55)
Q4 20171($0.56)($0.56)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dimension Therapeutics (NASDAQ:DMTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dimension Therapeutics (NASDAQ:DMTX)
Insider Ownership Percentage: 2.18%
Institutional Ownership Percentage: 85.43%
Insider Trades by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Institutional Ownership by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Insider Trades by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/7/2016K. Reed ClarkSVPSell5,000$10.00$50,000.00View SEC Filing  
10/27/2015Rishi GuptaDirectorBuy200,000$13.00$2,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dimension Therapeutics (NASDAQ:DMTX)
Latest Headlines for Dimension Therapeutics (NASDAQ:DMTX)
Source:
DateHeadline
americanbankingnews.com logoCitigroup Inc Downgrades Dimension Therapeutics Inc (DMTX) to Neutral
www.americanbankingnews.com - May 13 at 10:56 AM
News IconBRIEF-Dimension Therapeutics reports Q1 loss per share $0.54
www.businessinsider.com - May 12 at 10:21 PM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 12 at 9:31 AM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Releases Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 11 at 9:00 PM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 11 at 6:35 PM
finance.yahoo.com logoDimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 4:55 PM
marketbeat.com logoDimension Therapeutics reports 1Q loss
marketbeat.com - May 10 at 8:13 AM
americanbankingnews.com logo-$0.49 EPS Expected for Dimension Therapeutics Inc (DMTX) This Quarter
www.americanbankingnews.com - May 4 at 11:40 PM
americanbankingnews.com logoShort Interest in Dimension Therapeutics Inc (DMTX) Declines By 7.1%
www.americanbankingnews.com - May 4 at 1:01 AM
americanbankingnews.com logoDimension Therapeutics (DMTX) Receives Daily Media Impact Rating of 0.57
www.americanbankingnews.com - May 3 at 11:52 AM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 2 at 9:40 PM
americanbankingnews.com logoDimension Therapeutics (DMTX) Receiving Critical Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 28 at 10:29 AM
americanbankingnews.com logoDimension Therapeutics (DMTX) Getting Somewhat Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 25 at 7:37 PM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 21 at 10:38 PM
americanbankingnews.com logoDimension Therapeutics (DMTX) Earns Daily News Sentiment Rating of 0.20
www.americanbankingnews.com - April 21 at 2:35 PM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 18 at 7:57 PM
americanbankingnews.com logoDimension Therapeutics (DMTX) Getting Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 18 at 4:13 PM
americanbankingnews.com logoDimension Therapeutics (DMTX) Receiving Somewhat Negative Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 9:48 AM
finance.yahoo.com logoETFs with exposure to Dimension Therapeutics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 4:46 PM
americanbankingnews.com logoZacks Investment Research Lowers Dimension Therapeutics Inc (DMTX) to Hold
www.americanbankingnews.com - April 4 at 8:40 PM
americanbankingnews.com logoCantor Fitzgerald Comments on Dimension Therapeutics Inc's FY2017 Earnings (DMTX)
www.americanbankingnews.com - March 23 at 9:44 AM
finance.yahoo.com logoEdited Transcript of DMTX earnings conference call or presentation 9-Mar-17 1:30pm GMT
finance.yahoo.com - March 22 at 4:52 PM
finance.yahoo.com logoCan The Uptrend Continue for Dimension Therapeutics (DMTX)?
finance.yahoo.com - March 14 at 1:04 PM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Given a $3.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 12 at 9:27 PM
americanbankingnews.com logoDimension Therapeutics Inc (DMTX) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - March 10 at 11:04 AM
biz.yahoo.com logoQ4 2016 Dimension Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 5:19 PM
finance.yahoo.com logoDimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
finance.yahoo.com - March 9 at 5:19 PM
biz.yahoo.com logoDIMENSION THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 9 at 5:19 PM
biz.yahoo.com logoDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 9 at 5:19 PM
finance.yahoo.com logoDimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
finance.yahoo.com - March 7 at 11:59 AM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Dimension Therapeutics Inc.
finance.yahoo.com - February 14 at 5:37 PM
finance.yahoo.com logoDimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
finance.yahoo.com - February 7 at 5:53 PM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension ...
www.businesswire.com - February 2 at 5:11 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension Therapeutics, Inc.
finance.yahoo.com - February 2 at 5:11 PM
streetinsider.com logoDimension Therapeutics (DMTX) Reports Prelim. Data From Ongoing Phase 1/2 Clinical Program for DTX101
www.streetinsider.com - January 31 at 10:27 PM
us.rd.yahoo.com logoDimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
us.rd.yahoo.com - January 31 at 10:27 PM
streetinsider.com logoForm 8-K Dimension Therapeutics, For: Jan 31
www.streetinsider.com - January 31 at 5:25 PM
finance.yahoo.com logoDimension Therapeutics downgraded by Cantor Fitzgerald
finance.yahoo.com - January 31 at 5:25 PM
zacks.com logoFalling Earnings Estimates Signal Weakness Ahead for MiMedx Group (MDXG)
www.zacks.com - January 20 at 6:00 PM
biz.yahoo.com logoDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 20 at 6:00 PM
finance.yahoo.com logoDimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency
finance.yahoo.com - December 13 at 11:31 AM
globenewswire.com logoFirst COMP Positive Opinion for a Treatment in Development for GSDIa
globenewswire.com - November 29 at 5:42 PM
us.rd.yahoo.com logoDimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
us.rd.yahoo.com - November 29 at 5:42 PM
us.rd.yahoo.com logo8:03 am Dimension Therapeutics announces that the COMP of the EMA has issued a positive opinion recommending DTX401 for designation as an orphan medicinal product for the treatment of Glycogen Storage Disease Type Ia
us.rd.yahoo.com - November 29 at 5:42 PM
finance.yahoo.com logoDIMENSION THERAPEUTICS, INC. Financials
finance.yahoo.com - November 18 at 3:59 PM
finance.yahoo.com logoDimension Therapeutics Announces Presentation at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 3 at 4:17 PM
finance.yahoo.com logoDimension Therapeutics Announces Presentation at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 3 at 4:17 PM
finance.yahoo.com logo9:48 am Dimension Therapeutics will present a poster on AAV-based vectors for diverse therapeutic applications at ASH
finance.yahoo.com - November 3 at 4:17 PM
finance.yahoo.com logo9:48 am Dimension Therapeutics will present a poster on AAV-based vectors for diverse therapeutic applications at ASH
finance.yahoo.com - November 3 at 4:17 PM
globenewswire.com logoResearchers Report on New Technologies to Support Current and Next Generation HELA 2.0 AAV Manufacturing Platform
globenewswire.com - October 18 at 9:39 AM

Social

Chart

Dimension Therapeutics (DMTX) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff